MedPath
HSA Approval

TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML

SIN17089P

TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML

TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML

September 19, 2024

BEIGENE SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBEIGENE SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

L01FF09

Manufacturer Information

BEIGENE SINGAPORE PTE. LTD.

Boehringer Ingelheim Biopharmaceuticals (China) Ltd

Active Ingredients

Tislelizumab

100mg/10mL

Tislelizumab

Documents

Package Inserts

Tevimbra PI.pdf

Approved: September 19, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML - HSA Approval | MedPath